Clearing the smoke: What do we know about adolescent cannabis use and schizophrenia?

Journal of Psychiatry and Neuroscience

Volumn 39, Issue 2, 2014, Pages 75-77

  Hill, Matthew N ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABIS; CATECHOL METHYLTRANSFERASE; CIGARETTE SMOKE; ENDOCANNABINOID; TETRAHYDROCANNABINOL;

ADOLESCENT; CANNABIS USE; DOPAMINE RELEASE; EDITORIAL; HUMAN; PREFRONTAL CORTEX; SCHIZOPHRENIA; SEDATION; ANIMAL; BRAIN; CANNABIS ADDICTION; COMPLICATION; DRUG EFFECTS; PATHOPHYSIOLOGY; RISK FACTOR;

ADOLESCENT; ANIMALS; BRAIN; CANNABIS; HUMANS; MARIJUANA ABUSE; RISK FACTORS; SCHIZOPHRENIA;

EID: 84895427857     PISSN: 11804882     EISSN: 14882434     Source Type: Journal    
DOI: 10.1503/jpn.140028     Document Type: Editorial

References (32)

1. Mechoulam R, Parker LA. The endocannabinoid system and the brain. Annu Rev Psychol 2013; 64: 21-47.
2. Andréasson S, Allebeck P, Engstrom A, et al. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 1987; 2: 1483-6.
3. Malone DT, Hill MN, Rubino T. Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models. Br J Pharmacol 2010; 160: 511-22.
4. D'Souza DC, Sewell RA, Ranganathan M. Cannabis and schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci 2009; 259: 413-31.
5. Arseneault L, Cannon M, Witton J, et al. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 2004; 184: 110-7.
6. D'Souza DC, Perry E, MacDougall L, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004; 29: 1558-72.
7. Degenhardt L, Hall W, Lynskey M. Testing hypotheses about the relationship between cannabis use and psychosis. Drug Alcohol Depend 2003; 71: 37-48.
8. Peralta V, Cuesta MJ. Influence of cannabis abuse on schizophrenic psychopathology. Acta Psychiatr Scand 1992; 85: 127-30.
9. Rodriguez-Sanchez JM, Ayesa-Arriola R, Mata I, et al. Cannabis use and cognitive function in first-episode schizophrenia patients. Schizophr Res 2010; 124: 142-51.
10. Skosnik PD, Park S, Dobbs L, et al. Affect processing and positive symptom schizotypy in cannabis users. Psychiatry Res 2008; 157: 279-82.
11. Compton MT, Furman AC, Kaslow NJ. Lower negative symptoms scores among cannabis-dependent patients with schizophreniaspectrum disorders: preliminary evidence from an African American first-episode sample. Schizophr Res 2004; 71: 61-4.
12. Foti DJ, Kotov R, Guey LT, et al. Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am J Psychiatry 2010; 167: 987-93.
13. Hall W. Is cannabis use psychotogenic? Lancet 2006; 367: 193-5.
14. Harkany T, Keimpema E, Barabas K, et al. Endocannabinoid functions controlling neuronal specification during brain development. Mol Cell Endocrinol 2008; 286: S84-90.
15. Casey BJ, Giedd JN, Thomas KM. Structural and functional brain development and its relation to cognitive development. Biol Psychol 2000; 54: 241-57.
16. Heng L, Beverley JA, Steiner H, et al. Differential developmental trajectories for CB1 cannabinoid receptor expression in limbic/associative and sensorimotor cortical areas. Synapse 2011; 65: 278-86.
17. Volk DW, Lewis DA. Prefrontal cortical circuits in schizophrenia. Curr Top Behav Neurosci 2010; 4: 485-508.
18. Zamberletti E, Beggiato S, Steardo L, et al. Alterations of prefrontal cortex GABAergic transmission in the complex psychotic-like pheno type induced by adolescent delta-9-tetrahydrocannabinol exposure in rats. Neurobiol Dis 2014; 63: 35-47.
19. Rubino T, Realini N, Braida D, et al. The depressive phenotype induced in adult female rats by adolescent exposure to THC is associated with cognitive impairment and altered neuroplasticity in the prefrontal cortex. Neurotox Res 2009; 15: 291-302.
20. Chadwick B, Dickstein DL, Veuthey T et al. Adolescent THC ex-pos ure induces immediate and long-term alterations in the dendritic branching complexity of medial prefrontal cortical neurons. Soc Neurosci Abstr 2012; 73. 11.
21. Bossong MG, van Berckel BN, Boellaard R, et al. Delta-9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 2009; 34: 759-66.
22. Kuepper R, Ceccarini J, Lataster J, et al. Delta-9-tetrahydrocannabinol induced dopamine release as a function of psychosis risk: 18F-fallypride positron emission tomography study. PLoS ONE 2013; 8: e70378.
23. O'Donnell P. Adolescent maturation of cortical dopamine. Neurotox Res 2010; 18: 306-12.
24. Lee TT, Gorzalka BB. Timing is everything: evidence for a role of corticolimbic endocannabinoid in modulating hypothalamicpituitary-adrenal axis activity across developmental periods. Neuroscience 2012; 204: 17-30.
25. Chadwick B, Miller ML, Hurd YL. Cannabis use during adolescent development: suceptibility to psychiatric illness. Front Psychiatry 2013; 4: 129.
26. van Winkel R, Kahn RS, Linszen DH, et al. Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up. Arch Gen Psychiatry 2011; 68: 148-57.
27. Di Forti M, Iyegbe C, Sallis H, et al. Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biol Psychiatry 2012; 72: 811-6.
28. Caspi A, Moffitt TE, Cannon M, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 2005; 57: 1117-27.
29. Hickman M, Vickerman P, MacLeod J, et al. If cannabis caused schizophrenia-How many cannabis users may need to be prevented in order to prevent one case of schizophrenia? England and Wales calculations. Addiction 2009; 104: 1856-61.
30. Miller R, Ream G, McCormack J, et al. A prospective study of cannabis use as a risk factor for non-adherence and treatment dropout in first-episode schizophrenia. Schizophr Res 2009; 113: 138-44.
31. Rais M, Cahn W, van Haren N, et al. Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. Am J Psychiatry 2008; 165: 490-6.
32. Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994; 51: 273-9.